Key facts
- Notable investors include FuturePlay, Schmidt (South Korea).
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Eternox
- ·The full record, as it builds
Funding rounds
No funding rounds for Eternox are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eternox
Operator of a biotechnology company developing therapies to remove reactive oxygen species for the treatment of septic shock. The company specializes in extracorporeal removal of reactive oxygen species, incorporating selective adsorption materials, compatibility with existing critical care blood circulation systems, and use in refractory septic shock supported by preclinical animal survival data, targeting reduction of oxidative injury and inflammatory escalation, enabling intensive care units and hospitals treating severe sepsis to address high mortality where current pharmacologic interventions show limited effectiveness.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Ownership
- Privately Held (backing)
Eternox doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eternox shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eternox in its N-PORT filings yet. We sweep new filings monthly.